PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising cancer drug study halted early: what happened?
Disease control TerminatedThis study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific genetic changes (BRCA or HRD mutations) and had stopped responding to first treatment. The goal was to see if Promitil could slow or stop cancer growth. The study was ended e…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Lipomedix Pharmaceuticals Inc. • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New radioactive therapy targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-stage study tested a new radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, stomach, or brain cancers that had spread or come back. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
Cancer combo trial halted early: what we know
Disease control TerminatedThis study tested a combination of two drugs, niraparib and dostarlimab, in adults with advanced solid tumors that had DNA repair problems or were sensitive to platinum chemotherapy. The goal was to see how many patients' tumors shrank or disappeared. The trial was stopped early …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New cancer drug trial halted early: what we know
Disease control TerminatedThis early-stage trial tested a new drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have specific genetic changes (MAPK pathway). The study was stopped early, so results are limited. The goal was to find safe doses and see…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New drug tested for tough pancreatic cancer
Disease control TerminatedThis early study tested a new drug called BI 765883 in adults with advanced pancreatic cancer that had not responded to prior treatment. The goal was to find the highest safe dose when given alone or with chemotherapy, and to see if it could shrink tumors. The study was stopped e…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Pancreatic cancer surgery trial ends early – only 5 patients enrolled
Disease control TerminatedThis study looked at whether surgically removing small tumors in the liver or lungs (called oligometastases) could help people with pancreatic cancer live longer. All participants had already received chemotherapy before surgery. The trial was stopped early after enrolling only 5…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046052/SGN-EGFRd2, in people with advanced solid tumors like colorectal, lung, head and neck, and pancreatic cancers that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The study was terminated e…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New imaging agent shows promise for detecting Hard-to-Treat cancers
Diagnosis TerminatedThis study tested a new imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors, including glioblastoma and pancreatic cancer. The goal was to see how well it shows up on PET/CT scans and to check its safety. The study was stopped early, so results are limi…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated May 11, 2026 20:49 UTC
-
Antidepressant trial for pancreatic cancer patients falls short
Symptom relief TerminatedThis study looked at whether the antidepressant escitalopram could reduce depression in people with localized pancreatic cancer who were receiving chemotherapy before surgery. Only 4 people enrolled before the study was stopped early. The goal was to measure changes in depression…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated May 16, 2026 22:27 UTC